Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 08, 2023

SELL
$0.53 - $3.61 $36,577 - $249,144
-69,015 Reduced 83.33%
13,802 $50,000
Q1 2023

May 02, 2023

BUY
$0.54 - $0.91 $44,721 - $75,363
82,817 New
82,817 $54,000
Q1 2022

May 04, 2022

BUY
$1.03 - $1.77 $170,604 - $293,173
165,635 New
165,635 $245,000

Others Institutions Holding IKT

About Inhibikase Therapeutics, Inc.


  • Ticker IKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,227,100
  • Market Cap $50.5M
  • Description
  • Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointes...
More about IKT
Track This Portfolio

Track Hamilton Lane Advisors LLC Portfolio

Follow Hamilton Lane Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hamilton Lane Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hamilton Lane Advisors LLC with notifications on news.